Burning Rock Biotech (BNR) to Release Earnings on Wednesday

Burning Rock Biotech (NASDAQ:BNR) is expected to post its Q2 2026 results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($2.2883) per share and revenue of $19.2060 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, September 8, 2026 at 12:30 PM ET.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. Burning Rock Biotech had a negative return on equity of 10.98% and a negative net margin of 11.57%.The company had revenue of $15.66 million for the quarter, compared to analyst estimates of $19.21 million.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $10.19 on Monday. The business has a 50-day simple moving average of $9.49 and a two-hundred day simple moving average of $15.07. Burning Rock Biotech has a 52 week low of $6.79 and a 52 week high of $41.72. The company has a market cap of $107.20 million, a P/E ratio of -12.43 and a beta of 1.34. The company has a quick ratio of 2.81, a current ratio of 3.05 and a debt-to-equity ratio of 0.06.

Insiders Place Their Bets

In other news, Director Yusheng Han acquired 24,900 shares of the stock in a transaction on Friday, June 26th. The stock was acquired at an average price of $8.00 per share, with a total value of $199,200.00. Following the completion of the transaction, the director owned 18,404,086 shares of the company’s stock, valued at $147,232,688. This represents a 0.14% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders acquired 731,410 shares of company stock valued at $6,182,660 over the last 90 days. 30.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Burning Rock Biotech

An institutional investor recently bought a new stake in Burning Rock Biotech stock. Marshall Wace LLP acquired a new stake in Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 10,903 shares of the company’s stock, valued at approximately $220,000. Marshall Wace LLP owned approximately 0.10% of Burning Rock Biotech at the end of the most recent quarter. 30.03% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BNR shares. Wall Street Zen cut Burning Rock Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. Weiss Ratings downgraded shares of Burning Rock Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

About Burning Rock Biotech

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.